Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Cancer: early-phase trial registry
45 of 123 indexed Advanced Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #97 of 28,707 conditions by registered trial count.
123 US clinical trials · 45 currently recruiting · #97 of 28,707 conditions by registered trial count
Advanced Cancer: 123 US clinical trials tracked, 45 recruiting.
Advanced Cancer is the subject of 123 registered US clinical trials on ClinicalTrials.gov, 45 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 85 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition advanced-cancer
OPEN 45 | RECR 37% | LATE 2 | EARLY 85 | RANK #97 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Type 2 Diabetes (37% recruiting · 328 trials)
Advanced Cancer lists 45 open slots (37% of 123 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Cancer recruits in line with its size-band peers.
45 of 123 indexed trials (36.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Cancer research.
M.D. Anderson Cancer Center accounts for 19 of 123 trials (15.4%). 79 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 123 trials that report a genuine target (sentinel values excluded). 65 of those (52.8%) plan for fewer than 100 participants.
-
Advanced Cancer research is mostly interventional.
112 interventional and 11 observational studies make up this index (91.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
123 total, page 2 of 3
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
NCT01087554
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Xiuning Le
NCT03909334
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium
NCT05060432
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co.
NCT04396821
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen
NCT04354246
Effects of Mirtazapine on Appetite in Advanced Cancer Patients
M.D. Anderson Cancer Center
NCT00488072
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Arcus Biosciences
NCT06120075
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Verastem
NCT05375994
Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer
Memorial Sloan Kettering Cancer Center
NCT02112188
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
invoX Pharma Limited
NCT04648202
Care Planning Framework in Advanced Cancer (ABC123)
University of Colorado, Denver
NCT05408507
Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication
Dana-Farber Cancer Institute
NCT07147023
Identifying Family Members in Need of Support While Caregiving and After Loss
Memorial Sloan Kettering Cancer Center
NCT02455505
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
Arcus Biosciences
NCT05891171
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT04419532
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer
Tachyon Therapeutics
NCT05076552
Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Massachusetts Eye and Ear Infirmary
NCT04321954
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Ezra Cohen
NCT03568058
Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer
Memorial Sloan Kettering Cancer Center
NCT04435444
Assessing the Immunogenicity of pING-hHER3FL
Herbert Lyerly
NCT03832855
Measuring Sleep Disturbance Among Cancer Patients
M.D. Anderson Cancer Center
NCT00505544
Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors
BeiGene
NCT02407990
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer
Jazz Pharmaceuticals
NCT01361607
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
NCT02383212
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab
RAPT Therapeutics
NCT03674567
Care Transition Intervention for Hospitalized Patients With Advanced Cancer
Massachusetts General Hospital
NCT05142345
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
NCT01197170
A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Agenus
NCT03104699
Doxil, Bevacizumab and Temsirolimus Trial
M.D. Anderson Cancer Center
NCT00761644
The PediQUEST Response Intervention Study
Joanne Wolfe, MD, MPH
NCT03408314
Randomized Study of a Hospice Video Educational Tool for Patients With Advanced Cancer and Their Caregivers
Massachusetts General Hospital
NCT03040102
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Mirati Therapeutics
NCT02219711
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology
NCT03013218
Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT01339871
A Phase 1 Study in Participants With Advanced Cancer
Eli Lilly and Company
NCT01115790
Interactive Voice Response System in Advanced Cancer Patients
M.D. Anderson Cancer Center
NCT00625638
Biomarkers For Immune Checkpoint Inhibitors
Rhode Island Hospital
NCT04204434
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Bristol-Myers Squibb
NCT00798252
A Study of ARRY-334543 in Patients With Advanced Cancer
Array Biopharma, now a wholly owned subsidiary of Pfizer
NCT00278902
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
Pfizer
NCT01576406
Using Video Images to Improve Advance Care Planning in Patients With Cancer
Massachusetts General Hospital
NCT00970125
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
NCT04200963
A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced Cancer
CASI pharmaceuticals
NCT00658671
Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers
Tvardi Therapeutics, Incorporated
NCT03195699
A Dose-Escalation Study for Patients With Advanced Cancer
Eli Lilly and Company
NCT01214642
RDEA119 and Sorafenib Combination Dose Escalation Study
Bayer
NCT00785226
Care Transition Intervention for Patients With Cancer
Massachusetts General Hospital
NCT04640714
LY3214996 +/- HCQ in Pancreatic Cancer
Kimberly Perez, MD
NCT04386057
Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement
M.D. Anderson Cancer Center
NCT00507962
Oral Administration of STC-15 in Subjects With Advanced Malignancies
STORM Therapeutics
NCT05584111
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 71 |
| Phase 2 | 14 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Cancer page
123 registered trials, 45 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 45 Advanced Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Advanced Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Cancer condition card totals 123 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.